Data as of May 21
| -0.01 / -0.19%|
The 5 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 14.00 and a low estimate of 11.00. The median estimate represents a +146.68% increase from the last price of 5.27.
The current consensus among 6 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.